Bilayer tablet formulations

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8535715
APP PUB NO 20120282336A1
SERIAL NO

13509210

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ASTRAZENECA ABSE-151 85 SODERTALJE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Abebe, Admassu Princeton, US 8 42
Desai, Divyakant Princeton, US 10 85
Martin, Kyle Princeton, US 60 266
Patel, Jatin M Princeton, US 13 156
Timmins, Peter Wirral, GB 22 657

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 17, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00